合成针对SARS-CoV-2变体(VOC)的疫苗有效性(VE)的证据是紧迫和必要的。我们进行了系统评价和荟萃分析,以全面概述COVID-19疫苗抗VOC的有效性。
发表的随机对照试验(RCT),队列研究,以及评估VE对VOC(Alpha,Beta,Gamma,Delta,或Omicron)一直搜索到2022年3月4日。使用随机效应荟萃分析计算集合估计值和95%置信区间(CI)。VE定义为(1-估计值)。
11个RCT(161,388名参与者),20项队列研究(52,782,321名参与者),纳入26项病例对照研究(2,584,732例)。11种COVID-19疫苗(mRNA-1273,BNT162b2,ChAdOx1,Ad26。COV2.S,NVX-CoV2373,BBV152,CoronaVac,BBIBP-CorV,SCB-2019,CVnCoV,和HB02)包括在此分析中。完全接种疫苗对阿尔法有效,Beta,Gamma,Delta,和Omicron变体,VE为88.0%(95%CI,83.0-91.5),73.0%(95%CI,64.3-79.5),63.0%(95%CI,47.9-73.7),77.8%(95%CI,72.7-82.0),和55.9%(95%CI,40.9-67.0),分别。加强疫苗接种对Delta和Omicron变体更有效,VE为95.5%(95%CI,94.2-96.5)和80.8%(95%CI,58.6-91.1),分别。mRNA疫苗(mRNA-1273/BNT162b2)似乎对VOC的VE高于其他疫苗;在VE和疫苗类型之间观察到显着的相互作用(p相互作用<0.10)(mRNA疫苗与不是mRNA疫苗)。
完全接种COVID-19疫苗对α变体非常有效,和中等有效的贝塔,Gamma,和Delta变体。加强疫苗接种对Delta和Omicron变体更有效。mRNA疫苗似乎对α有更高的VE,Beta,Gamma,和Delta的变体。
It was urgent and necessary to synthesize the evidence for vaccine effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a systematic review and meta-analysis to provide a comprehensive overview of the effectiveness profile of COVID-19 vaccines against VOC.
Published randomized controlled trials (RCTs), cohort studies, and case-control studies that evaluated the VE against VOC (Alpha, Beta, Gamma, Delta, or Omicron) were searched until 4 March 2022. Pooled estimates and 95% confidence intervals (CIs) were calculated using random-effects meta-analysis. VE was defined as (1-estimate).
Eleven RCTs (161,388 participants), 20 cohort studies (52,782,321 participants), and 26 case-control studies (2,584,732 cases) were included. Eleven COVID-19 vaccines (mRNA-1273, BNT162b2, ChAdOx1, Ad26.COV2.S, NVX-CoV2373, BBV152, CoronaVac, BBIBP-CorV, SCB-2019, CVnCoV, and HB02) were included in this analysis. Full vaccination was effective against Alpha, Beta, Gamma, Delta, and Omicron variants, with VE of 88.0% (95% CI, 83.0-91.5), 73.0% (95% CI, 64.3-79.5), 63.0% (95% CI, 47.9-73.7), 77.8% (95% CI, 72.7-82.0), and 55.9% (95% CI, 40.9-67.0), respectively. Booster vaccination was more effective against Delta and Omicron variants, with VE of 95.5% (95% CI, 94.2-96.5) and 80.8% (95% CI, 58.6-91.1), respectively. mRNA vaccines (mRNA-1273/BNT162b2) seemed to have higher VE against VOC over others; significant interactions (pinteraction < 0.10) were observed between VE and vaccine type (mRNA vaccines vs. not mRNA vaccines).
Full vaccination of COVID-19 vaccines is highly effective against Alpha variant, and moderate effective against Beta, Gamma, and Delta variants. Booster vaccination is more effective against Delta and Omicron variants. mRNA vaccines seem to have higher VE against Alpha, Beta, Gamma, and Delta variants over others.